MedWatch

US downswing reflects shift in underlying demand, says Demant CEO

Demand for hearing aids on the US market will return in the future, according to Demant CEO Søren Nielsen, who thinks people are postponing the decision to acquire a device due to the challenging economic environment.

Photo: Demant / PR

The downswing on the US hearing aid market, which has impacted the expectations of both Danish Demant and Swiss Sonova, is the biggest isolated event that has changed the game for the Danish hearing aid manufacturer.

Even so, the underlying picture hasn’t undergone structural changes, says Demant’s chief executive, Søren Nielsen, who is expecting demand for hearing aids to return at a later point in time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs